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Abstract
Background: Human papillomavirus (HPV) 16 and 18 are the two most common HPV oncogenic types that can be
prevented by vaccination. This study aimed at assessing the cost-effectiveness of 3 doses of the bivalent HPV vaccine
in rural and urban settings in China.
Methods: A Markov model was adapted to reflect the lifetime of a modelled 100,000 12-year-old girls cohort in rural
and urban settings in China. Input parameters were obtained from published literature, official reports and a
two-round expert review panel. Clinical and economic outcomes of vaccination at age 12 with screening was
compared to screening only. In the base case analysis, a 3 % discount rate, the vaccine cost of 247 CNY (US$
39, PAHO vaccine cost in 2013), two rounds of screening in a life time and 70 % coverage for both screening
and vaccination were used. One-way, two-way and probabilistic sensitivity analyses were performed. We used
different thresholds of cost-effectiveness to reflect the diversity of economic development in China.
Results: Vaccination in addition to screening could prevent 60 % more cervical cancer cases and deaths than
screening only. The incremental cost effectiveness ratio varied largely when changing cost of vaccination and discount in
one way analysis. Vaccination was very cost-effective when the vaccine cost ranged 87-630 CNY (US$ 13.8-100) in rural
and 87-750 CNY (US$ 13.8–119) in urban; and remained cost-effective when the vaccine cost ranged 630–1,700 CNY (US$
100–270) in rural and 750–1,900 CNY (US$ 119–302) in urban in two way analysis. Probabilistic sensitivity analyses showed
that model results were robust.
Conclusions: In both rural and urban, the vaccination cost and discounting are important factors determining
the cost-effectiveness of HPV vaccination; policy makers in China should take these into account when making a
decision on the introduction of HPV vaccine. In areas with a high burden of cervical cancer and limited screening
activities, HPV vaccination should be prioritized. However, the vaccine cost needs to be reduced in order to make it
very cost-effective and affordable as well, in particular in poverty areas with high disease burden.
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Background
Given its large population, China accounted for 11.7 %
of the world’s cervical cancer (CC) cases and 11.3 % of
the world’s CC deaths in 2012 [1]. Since 2009, a screen-
ing programme has been implemented in rural China
targeting women aged 35 to 64 years, which has
gradually expanded from screening 10 million women
over a period of 3 years to screening 10 million women
per year. Women in urban areas have access to CC
screening on an opportunistic basis or through their em-
ployment. However, the mortality was reported to
increase at an annual rate of 4.1% in young urban
women aged 35 to 44 [2]. Furthermore, there are also
wide disparities in CC incidence, mortality and screening
accessibility between rural and urban areas in China [3].
Persistent HPV infection is the main cause of CC [4].
Seventy percent of all CC worldwide is caused by HPV
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16/18 [5]; in China, HPV 16/18 infection accounts for
84.5 % of squamous cell carcinoma [6]. Prophylactic
HPV vaccines may add to current efforts of screening
in reducing CC burden in China. There are currently
two vaccines available globally: a bivalent vaccine pro-
duced by GSK (Cervarix®) and a quadrivalent vaccine
produced by Merck (Gardasil®). Both vaccines protect
against HPV types 16 and 18 while the quadrivalent
vaccine also protects against non-oncogenic types 6
and 11. Cervarix®, a bivalent vaccine (GSK, Wavre,
Belgium) has been widely used in over 100 countries
through regional or national immunization programs to
prevent HPV 16/18 infection and related diseases.
Cervarix® has shown high immunogenicity and safety, and
induces a high degree of protection against HPV-16/18
infection and associated cervical lesions [7, 8]. To date,
only Cervarix® has just been approved by Chinese Food
and Drug Administration in July 2016 after completation
of phase III clinical trials using 3 doses of bivalent HPV
vaccination (3DBV) in mainland China [9, 10].
Because the HPV vaccine is relatively costly [11], it
has been subject to careful scrutiny. With the increas-
ing importance of economic evaluation in priority
setting for health [12], the cost-effectiveness of vac-
cination strategies should be considered before inclu-
sion in national programmes, as recommended by the
World Health Organization (WHO) position paper on
HPV vaccines [13]. Mathematical models can help to
estimate the long term effectiveness of HPV vaccin-
ation in parallel to clinical trials. Such models use a
simplified description of the natural history leading to
cervical cancer and provide a formal framework to
synthesize information from various sources [14].
Modelling studies can integrate currently available
clinical data with country-specific epidemiological
data to evaluate the potential long-term impact of
adding vaccination to screening [15].
Given the important resource implications of intro-
ducing the HPV vaccine in China, the financing of
the HPV vaccination programme needs to be carefully
considered to ensure the best use of resources com-
pared to other priorities in China [16–18]. To date,
there have been few comprehensive analyses evaluat-
ing the long-term impact of the HPV vaccine in
China [19, 20]. Furthermore China is characterized by
substantial differences in economic development and
disease distribution between regions and therefore the
diversity of economic, the ability to pay and screening
influence should be considered to achieve the health
care fairness. In such context, it is important to ad-
vance equity in China’s health system if implementing
HPV vaccination in national vaccination program. We
aimed to estimate the cost-effectiveness of HPV vac-
cination using Chinese specific parameters.
Methods
Model structure
This study was approved by the Human Subjects
Review Boards (Approval No. 13-066/742) of the
Cancer Institute and Hospital, Chinese Academy of
Medical Sciences (CICAMS). We used a Markov
model developed in Microsoft Excel to evaluate the
long-term clinical effectiveness and cost-effectiveness
of the bivalent vaccine in both rural and urban China
for a hypothetical cohort of 100,000 12-year-old girls
(Additional file 1: Figure S1).
The Markov model was adapted from previously pub-
lished models by Debicki [21] and Konno [22] and has
been used to perform cost-effectiveness analyses in
other countries such as Canada, Taiwan and Japan. The
model simulated the natural history of cervical cancer
(extending from infection to death) in the hypothetical
cohort of 12-year-old girls who are vaccinated in
addition to current screening or screening only for cer-
vical cancer, with follow up for a life-time. The Markov
model has a cycle time of 1 year and run over life-time
of the cohort according to the mortality rate for women
reported by National Bureau of Statistics of China [23].
Study parameters were obtained through expert review,
literature review and data extraction from previous
studies. The study did not collect information from pa-
tients and informed consent was therefore not needed.
A 3 % discount rate was used with a range (0–5 %) for
sensitivity analysis according to the WHO guidelines
[24]. The same discount rates for health outcomes and
costs were used.
Perspective
Globally, cervical cancer is considered an important public
health problem and disease burden could be reduced by
HPV vaccines. In developing countries, the main challenge
for the introduction of the HPV vaccine is its price.
Evidence from Mexico, Panama and other developing
countries showed high vaccination coverage when includ-
ing HPV vaccine in the national immunization programs
by government [25]. Based on the successful experience of
hepatitis B vaccine in China, we assumed the government
would strengthen the vaccination of HPV according to
the China National Plan for NCD Prevention and
Treatment [26]. We expect our cost-effectiveness mod-
elling analysis could benefit the health policy, especially
public health policy decisions and budget-impact.
Based on the considerations above, we chose the
health care payer perspective [27] and considered only
direct medical costs.
Model validation
The model was validated by comparing the modelled
age-specific incidence and mortality of CC in rural and
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urban China with national register and statistical data
[3, 28]. As shown in Fig. 1, the results showed that
the modelled cervical cancer incidence and mortality
were not significantly different from cancer registry
data (r = 0.985, 0.973, 0.954 and 0.952 for rural inci-
dence, urban incidence, rural mortality and urban
mortality respectively).
Base case analysis
The base case analysis was conducted for a hypothetical
cohort of 100,000 12-year-old girls. We considered two
scenarios: HPV vaccination in addition to screening
against screening only, separately for rural and urban
areas. The cost-effectiveness of HPV vaccination was
evaluated by comparing the two scenarios.
The screening and treatment costs were collected by
a micro-costing approach [29] from previous studies
[30, 31] to estimate aggregated costs associated with
cervical cancer, and re-evaluated by a two round expert re-
view panel. Since most patients in China with diagnostically
confirmed CC seek treatment in urban hospitals, only the
treatment cost of CC in urban areas was estimated. Costs
were calculated in Chinese Yuan (CNY), and converted to
US dollars (US$) at an exchange rate of 1 US$ = 6.3 CNY
for 2013. The two round expert panel lasted for five months.
Eight rural and twelve urban clinical gynecologists,
epidemiologists and economists chosen from Northern
(Beijing, Tianjin, Liaoning), Central (Henan, Shanxi,
Jiangsu), Western (Xinjiang) and Southwestern (Sichuan) of
China were selected to evaluate the costs of screening, costs
of treatment and the proportions of women receiving or re-
fusing the treatment procedures for cancer patients [32].
China is not a member of the Global Alliance for Vac-
cines and Immunization (GAVI) or the Pan American
Health Organization (PAHO) [33, 34], but we assumed
China could likely negotiate lower public sector prices
[35]. Since China’s GDP per capita is similar to most
PAHO countries, such as Peru, Brazil and Chile [34, 36],
we assumed in the base case analysis a vaccine cost simi-
lar to the PAHO cost (247 CNY (US$ 39) in 2013). In
addition, since HPV vaccine price has not been available
in China, we obtained the unit cost of vaccine adminis-
tration from a previous publication on hepatitis B
vaccination [37]. We assumed that the HPV vaccine
would be delivered through the expanded programme
on immunisation (EPI) and would rely on the existing
management system (personnel, equipment, cold chain
etc.). We therefore only considered the incremental cost
of adding the HPV vaccine to the EPI programme, and
included the cost of salaries, surveillance, propaganda,
training, supervision, transportation, cold chain and
other equipments that were related to vaccine delivery.
The incremental vaccine administration cost for an add-
itional dose of hepatitis B vaccine was 18 CNY (US$ 3)
per child per dose [37] and therefore 54 CNY (US$ 9)
for 3-doses of the HPV vaccine. The administration cost
was assumed to be the same in rural and urban settings,
since our analysis was under the scenario of government
supported national vaccination program based on the
experience of the hepatitis B vaccine.
Fig. 1 Comparison of data generated from the model with the Chinese cancer registry report (a: CC incidence in rural, b: CC incidence in urban,
c: CC mortality in rural, d: CC mortality in urban)
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The utilities in our model have been used in previ-
ously published studies [38–42]. The model assumed
no decrements in utility from competing morbidities
for non-infected, non-disease-stage subjects. The data
of transition probabilities were calculated from the
CICAMS pooled database which included more than
30,000 women across China of 17 population-based stud-
ies in 9 provinces (Shanxi, Beijing, Henan, Jiangxi,
Xinjiang, Shanghai, Jiangsu, Gansu and Guangdong) [43],
expert panel and derived from the literature [44–48]. In
general, HPV infection increases in young women after
sexual debut, but a majority proportion of the HPV in-
fection among young female clears on its own. The
HPV incidences were calculated from the CICAMS
database [43]. We assumed the age of first sexual debut
at 15-year-old in Chinese girls (and therefore assumed
no HPV infection in girls under the age of 15 years).
The CICAMS database showed that HPV incidence in-
creased from 15-year-old to 25-year-old and decreased
from 25-year-old to 40-year-old, then increased again
from 40 to 60-year-old [43].
The vaccine efficacy parameters varied with different
degrees of cervical intraepithelial neoplasia (CIN1, CIN2
and CIN3). A 93.2 % overall vaccine efficacy against CC
irrespective of types, 64.9 % efficacy against CIN2/3 irre-
spective of types and 50.3 % against CIN1 irrespective of
types were assumed in the model [49]. The vaccine
coverage was assumed at 70 % both in rural and urban
according to the hepatitis B vaccination uptake after 3
years on the market.
The 70 % screening coverage was obtained from cross-
sectional studies in China [50, 51]. Screening in rural areas
is currently done using Pap smear or visual inspection
with acetic acid/Lugol’s iodine (VIA/VILI) [52, 53], while
in urban areas Pap smear is the only used primary screen-
ing method according to the survey and the expert review
panel [32, 54]. The screening sensitivities for CIN1 and
CIN2/3 were calculated from the CICAMS database [43].
Both screening scenarios assumed in a lifetime screening
at ages 35 and 45, according to cervical cancer screening
guidelines for developing countries [55].
The main outcome measure used in the model was the
ICER (Incremental Cost-effectiveness Ratio = Incremental
Cost per Quality-adjusted Life-years (QALYs)). As there
are substantial differences in economic development
between rural and urban China, and there is no data on
GDPs for rural and urban areas separately, the cost-
effectiveness threshold should be considered carefully. We
evaluated the cost-effectiveness results against 2 different
thresholds in the base case analysis: the intervention was
considered very cost-effective if the ICER was less than
one time the country’s GDP (i.e., 41,908 CNY, US$
6,652) and cost-effective if the ICER was less than three
times the country’s GDP (i.e., 125,723 CNY, US$
19,956) [55, 56]. Other measures including the number of
cervical cancer cases prevented, deaths avoided, and aver-
age life-years and QALY gained for one age cohort were
studied over lifetime. In addition, accumulated cost and
QALY gained per woman, plus the ICER of 3DBV
programme versus screening were calculated. The main
input parameters are shown in Additional file 2: Table S1.
One-way sensitivity analysis
One-way sensitivity analysis was performed to account
for methodological, structural and parameter uncer-
tainties and assumptions. The changes of values used
were listed in Additional file 2: Table S1. In one-way
sensitivity analysis, one parameter would be changed
in a certain range while other parameters were kept
constant. Most parameters were varied by +/- 20 %
from the base case, with the exception of the vaccine
cost. The vaccine cost (for 3 doses) was varied from
a minimum of 87 CNY (US$ 13.8) which is the GAVI
cost to 1,900 CNY (US$ 302) which is the Hong
Kong listed private sector cost [33, 34]. Other param-
eters that were examined in the sensitivity analysis in-
cluded the discount rate (0/5 %), vaccine efficacy (95
% confidence interval, 95 % CI), screening age (-/+ 5
years) and the vaccination age (12/18 years).
Two-way sensitivity analysis
Two-way sensitivity analysis was conducted by varying
both the vaccine cost from 87 CNY (US$ 13.8) to 1,900
CNY (US$ 302) per course and another parameter, ei-
ther the discount rate (0/5 %), CC mortality (+/- 20 %
from the base case), or screening coverage (30/50 %
screening coverage). These three parameters were in-
cluded in the two-way sensitivity analysis for the
following reasons: the discount rate has been shown to
be an important parameter that may affect cost-
effectiveness results; the CC mortality may vary across
different regions of China and the screening coverage
can be improved with adequate resources and may
therefore change over time. According to base case,
which using three times national GDP as the threshold
of cost-effectiveness and one time national GDP as the
threshold of very cost-effectiveness, the two-way sensi-
tivity analysis would also be conducted in the two
thresholds. In addition, taking into account the tremen-
dous varieties of China’s current screening coverage in
all regions, screening coverage evaluation were paid spe-
cially attention in the analyses. As 70 % screening cover-
age were extracted from well-designed research studies,
we set 70 % as the base case screening coverage but for
the current screening status, the screening coverage
would be extremely low (6.25 % in rural and 21.5 % in
urban). As a result, a lower screening coverage (30 and
50 %) would be analysed in two way price threshold
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sensitivity analyses and 70 % were assumed to be the
idealized screening coverage.
Probabilistic sensitivity analysis (PSA)
In the PSA, all the main input parameters were changed
for each calculation. The combined effect of variations in
model inputs were explored via multivariate PSA using
@Risk® software (Palisade Corporation) in the Excel
model. Distributional functions were assigned to each
variable for probabilistic sensitivity analysis to evaluate the
robustness of the results.
In PSA, the input distributions were set to be normal
distributions (limited between 0 and 1 for transition
probabilities) when 95 % CI and Standard Deviations
(SD) were available. Otherwise, the uniform distribution
with a variation +/- 20 % was used when there were no
mean, SD or ranges available (Additional file 2: Table S1).
In total, 10,000 samples were generated from the assigned
distribution.
Results
Table 1 showed the base case results for the clinical and
economic evaluation. Though cervical cancer can be
reduced by effective preventive measures, cervical cancer
cases would be missed due to the clinical performances
of screening methods. Under the circumstances of the
current screening methods in rural and urban, there
were 747 cases and 354 deaths occurred in rural, 913
cases and 341 deaths occurred in urban respectively in
only screening scenario (Table 1). The combination of
vaccination with 3 doses of the bivalent HPV vaccine
and screening was estimated to prevent 455 and 557
more cervical cancer cases as well as 215 and 208 more
deaths than screening only among 100,000 girls, respect-
ively. This result showed that vaccination in addition to
screening could prevent 60 % more cervical cancer cases
and deaths than screening only in China.
Under the circumstance that girls were regularly
screened twice in their life time, considering the 3 % dis-
count rate, 70 % screening and vaccination coverage and
PAHO cost, HPV vaccination had an ICER of 11,365
CNY (US$ 1804) in rural and 6124 CNY (US$ 972) in
urban, which is much lower than the national GDP 2013
(41,908 CNY, US$ 6652), which meant that HPV vaccin-
ation was very cost effective in this context.
Sensitivity analyses
The most influential factors on whether adding HPV
vaccination to screening are cost-effective or not were
evaluated in Fig. 2. The ICER varied largely when chan-
ging cost of vaccination (ICER ranged 142,110 CNY in
rural and 132,128 CNY in urban), and discount (ICER
ranged 49,272 CNY in rural and 42,885 CNY in urban)
in one way sensitivity analysis. Other parameters, such
Table 1 Base case cost-effectiveness results without discounting and with discount rate 3 % for both costs and benefits
Rurala Screening only (A) Screening + vaccination (B) Difference (B-A) ICER (CNY per QALY gained) ICER (US$ per QALY gained)
Undiscounted
Cost (CNY) 64,386,901 48,641,712 −15,745,190
Life-years 6,822,557 6,826,325 3768
CC cases 747 292 −455
CC deaths 354 139 −215
QALYs 6,821,273 6,825,826 4553 −3458 −549
Discounted
Cost (CNY) 19,627,341 29,777,012 10,149,672
QALYs 2,934,012 2,934,905 893 11,365 1804
Urbana Screening only (A) Screening + vaccination (B) Difference (B-A) ICER (CNY per QALY gained) ICER (US$ per QALY gained)
Undiscounted
Cost (CNY) 92,026,104 62,240,211 −29,785,893
Life-years 7,241,077 7,244,914 3837
CC cases 913 356 −557
CC deaths 341 133 −208
QALYs 7,239,157 7,244,167 5011 −5944 944
Discounted
Cost (CNY) 28,711,710 34,593,492 5,881,781
QALYs 3,001,172 3,002,133 961 6124 972
CC Cervical Cancer, QALYs Quality-adjusted Life-years, CNY Chinese Yuan, US$ United States Dollar, ICER Incremental Cost-effectiveness Ratio
a100,000 subjects
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as CC mortality, HPV infection, progression rate, vac-
cine efficacy, treatment cost of precancerous lesions,
utility, age of screening and age at vaccination had little
influence on the cost-effectiveness results. Shown from
the one-way sensitivity analysis, when the CC mortality
decreased, the HPV infection decreased, the vaccine effi-
cacy against all cervical cancers irrespective of type
decreased or the screening sensitivity increased, the
vaccine cost should be reduced in order to remain the
same ICER. In rural, the results showed that the most
influential factors were cost of vaccination, discount rate,
HPV infection rate, progression rate and vaccine efficacy
(See Panel a). In urban, the most influential factors were
cost of vaccination, discount rate, HPV infection rate,
progression rate and cost of cancer (See Panel b). For
screening coverage additionally, HPV vaccination was still
very cost-effective (ICER = 14,761 CNY, US $ 2343 in rural
and ICER = 9702 CNY, US$ 1540 in urban) with PAHO
cost even in areas with 100 % screening coverage. In areas
with the current low coverage (6.25 % [57] in rural and
21.5 % in urban [28]), the ICER would be 6463 CNY
(US$ 1026) and 2135 CNY (US$ 339) in rural and
urban areas, respectively. Under this circumstance, the
3DBV was estimated to be very cost-effective in both
rural and urban.
The two-way sensitivity analysis showed the relationship
between vaccine cost and three parameters identified in
the one-way sensitivity (Fig. 3). Taken rural areas (Panel a,
b, c) as an example, in panel a, the blue line with round
dot was the results with 5 % discount; the blue line with
square dot was the results with 3 % discount (base case
value); the blue line with the diamond dot was the
results with 0 % discount. The black lines showed the
thresholds of cost effectiveness (three times national
Fig. 2 One-way sensitivity analysis: effects of varying factors on ICER in rural settings and urban settings. a One-way sensitivity analysis in rural
settings. b One-way sensitivity analysis in urban settings. CC = cervical cancer; Pre CC to CC = transition probabilities from pre-cancer to cancer;
CIN 23 to CC = Progression rate from CIN2/3 to pre-cancer; VE against CC = vaccine efficacy against cervical cancer; VE against CIN1 = vaccine
efficacy against CIN1; VE against CIN2/3 = vaccine efficacy against CIN2/3
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GDP) and very cost effectiveness (one time national
GDP). Shown from panel a with 3 % discount, HPV vac-
cination was very cost-effective if the price was lower than
630 CNY (US$ 100) and it was cost-effective if the price
was lower than 1700 CNY (US$ 270) in rural areas. With
discount rate increased, the cost of HPV vaccine should
be reduced to be cost-effective. On the other hand, with
discount rate decreased, it was still cost-effective with the
price of 1900 CNY (US$ 302). Similarly, for areas with
higher CC mortality, HPV vaccination could be more
cost-effective than in areas with lower CC mortality (See
panel b). For areas with extremely lower screening cover-
age, HPV vaccination could be more cost-effective than in
areas with higher screening coverage (See panel c). In
urban, vaccination varied from very cost-effective to
cost-effective with the national threshold when the vac-
cine cost ranged from 750 CNY (US$ 119) to 1900 CNY
(US$ 302) in base case (Fig. 3, panel d, e, f ).
Figure 4 showed the PSA in rural and urban. Each
blue dot on the graph represented the relative dis-
counted/undiscounted ICER of one out of the 10,000
simulations. X-axis represented the incremental QALYs
and y-axis represented the incremental costs. The red
dots represented the average value and the blue dots
represented each replicates.
For rural setting, when comparing vaccination in addition
to screening with screening only, with 3 % discount, 95.8 %
of the replicates predicted to have greater lifetime costs and
greater QALY benefit than the screening only scenario
(Quadrant I of Fig. 4a). 4.2 % of dots fell into Quadrant II
meant that vaccine combined with screening would cost
less but gained more QALYs than screening only (Quadrant
II in Fig. 4a). When undiscounted, 10.2 % of the replicates
predicted to have greater lifetime costs and greater QALY
benefit than the screening only in rural (Quadrant I of
Fig. 4b). 89.8 % of dots fell into Quadrant II meant that vac-
cine combined with screening would cost less but gained
more QALYs than screening only (Quadrant II in Fig. 4b).
For urban setting, when comparing vaccination in addition
to screening with screening only, with 3 % discount, 75.5 %
of the replicates predicted to have greater lifetime costs and
greater QALY benefit than the screening only scenario
(Quadrant I of Fig. 4c). 24.5 % of dots fell into Quadrant II
meant that vaccine combined with screening would cost
less but gained more QALYs than screening only (Quadrant
II in Fig. 4c). When undiscounted, 0.5 % of the replicates
predicted to have greater lifetime costs and greater QALY
benefit than the screening only in urban (Quadrant I of
Fig. 4d). 99.5 % of dots fell into Quadrant II meant that vac-
cine combined with screening would cost less but gained
more QALYs than screening only (Quadrant II in Fig. 4d).
The results showed that most of the replicates were in
Quadrant I with 3 % discount and Quadrant II with 0 %
discount, showing that vaccination in addition to screen-
ing had greater QALY benefit compared to screening
only. All the replicates were less than the threshold of 3
times national GDP, that represented 100 % of replicates
were cost-effectiveness in rural and urban respectively.
Discussion
The ongoing screening programme with conventional
Pap smear or visual inspection will inevitably miss
many pre-cancer lesions due to the limitations of these
two methods and the lack of health care workers [58].
Moreover, almost ten years delay of the HPV vaccine in
China would cause more than 59 million Chinese girls
Fig. 3 Effects of vaccine price and main factors in rural settings and urban settings. a Vaccine cost and discount rate effects in rural. b Vaccine
cost and CC mortality effects in rural. c Vaccine cost and screening coverage effects in rural. d Vaccine cost and discount rate effects in urban. e
Vaccine cost and CC mortality effects in urban. f Vaccine cost and screening coverage effects in urban
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aged 9-15 to lose their opportunities for vaccination
[35] and put 206,000 girls at high risk for cervical can-
cer over the next 25 years [59]. HPV vaccine may
add to current efforts of screening in reducing cervical
cancer burden in China in the future.
In the current screening programme, considering the dif-
ferent situation in rural and urban areas, our study analysed
two screening strategies respectively to reflect the difference
in screening practice between rural and urban settings.
Input parameters for rural and urban differed by
HPV incidence, proportion of precancers treated,
screening and treatment costs for precancerous le-
sions. The vaccine coverage was assumed the same (70 %)
in rural and urban based on the perspective that govern-
ment would include HPV vaccine in the national vaccination
program as well as the success experiences of Hepatitis B
vaccine in China. We also set the same methods for cancer
treatment between rural and urban, given the realistic situ-
ation that most of the rural patients with diagnostically con-
firmed cervical cancer would seek for treatment in the
urban hospitals due to no cancer therapeutic capacity in
rural areas. The administration cost was US$ 9 per course,
Fig. 4 Probabilistic sensitivity analyses in rural and urban. a Probabilistic sensitivity analyses with discounted in rural. b Probabilistic sensitivity analyses with
undiscounted in rural. c Probabilistic sensitivity analyses with discounted in urban. d Probabilistic sensitivity analyses with undiscounted in urban.
(Note: X-axis represents the incremental QALYs and y-axis represents the incremental costs. Each blue dot on the graph represents the
relative discounted/undiscounted ICER of one out of the 10,000 simulations and the red dot represents the average value. Quadrant I represents comparing
with screening only, vaccine and screening would gain more QALYs with the costs increasing. Quadrant II represents comparing with screening only,
vaccine and screening would gain more QALYs with the costs decreasing. Quadrant III represents comparing with screening only, vaccine and screening
would lose more QALYs with the costs decreasing. Quadrant IV represents comparing with screening only, vaccine and screening would lose more QALYs
with the costs increasing. Quadrant II means vaccine and screening would be more cost-effective compared with screening only. Quadrant IV means
screening only would be more cost-effective compared with vaccine and screening)
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which was similar to previous published studies [18, 60].
The main findings showed that vaccination with 70 % cover-
age of 3DBV in 12-year-old girls in addition to screening
could prevent 60 % more cervical cancer cases and deaths
than screening only in China. In a case-control study in
United States [61], the prevalence of HPV16/18 in CIN2+
lesions was demonstrated to decrease from 53.6 to 28.4 %
among women received at least one dose of HPV vaccine
(Ptrend < 0.001), which could lead to the reduction of cervical
cancer in the future.
The perspective of health care payer was used in this
study. Compared with societal perspective which consid-
ered the patient time, travel costs, willingness-to-pay
and many other indirect parameters, the health care
payer perspective could provide more information for
the informing budget impact and policy decisions. As
decisions on introduction of vaccines are often influ-
enced by funding agencies, analysis such as budget
impact assessments focusing on cost-saving, affordability
and sustainability are relevant in resource-constrained
settings [18, 62, 63]. The costs borne by providers (e.g.,
donors and governments) which separated by patients
and their families could allow judgments to be made
from the viewpoints of the various decision-makers.
This is particularly important for middle and low in-
come countries that may be required to fully-finance
the cost of vaccines. Lieu [64] estimated (based on
existing knowledge about the vaccine at the time) that
from the health care payer perspective pneumococcal
vaccination of healthy infants in the United States
would result in savings if the vaccine cost US$ 18 or less
per dose, but from the societal perspective, the vaccination
programme would result in savings if the vaccine cost US$
46 or less per dose. Analysts should therefore be cognizant
that whilst a broader perspective that includes productivity
losses (gains) will improve cost-effectiveness, it can also be
used to justify higher vaccine cost, as it increases the
break-even price per dose, i.e., the price at which the cost
of the vaccination programme is exactly off-set by the
savings due to vaccination [65].
In the sensitivity analysis, whether the results were cost-
effective or not depended on the variability of the key input
parameters. HPV vaccination was very cost-effective if the
price was lower than 630 CNY (US$ 100) in rural and 750
CNY (US$ 119) in urban in two-way analysis. In order to
be very cost-effective, the vaccine cost should be reduced in
areas with lower cervical cancer mortality and higher
screening coverage. Health care payers should compare the
economic development level with the national thresh-
old, CC mortality, HPV infection, HPV genotypes
distribution, screening coverage, screening methods
and other dominant parameters to decide the appropri-
ate vaccination price. Global cost-effectiveness analysis
informed by country-based evidence suggests that
vaccinating pre-adolescent girls can be cost-effective,
particularly in resource-constrained settings where
alternative cervical cancer prevention and control mea-
sures often have limited coverage [66–69]. In the base
case, we assumed the screening coverage as 70 % accord-
ing to the previous research studies in China [50, 51], the
coverage rate in real world setting would be much lower,
for an instance, it was only 21.5 % in urban [28] and 6.25 %
[57] in rural so far. For areas with low screening coverage
and high cervical cancer burden, HPV vaccination could
be more cost-effective and more urgent to be included into
the vaccination plans.
Due to the diverse economic development of China,
the different areas have different affordability profile.
Since 2008, Panama has been the first country in Latin
America and the Caribbean to provide the HPV vaccine
free of charge to young adolescent girls [70]. After that,
many developing countries have implemented the HPV
vaccine [71, 72] into national programmes. In China, the
government would strengthen the vaccination of HPV
according to the China National Plan for NCD Preven-
tion and Treatment [26]. However, the vaccine coverage
and price would be the critical factors to be considered
in the planning of vaccination programme.
In order to promote the implementation of HPV vac-
cine in China, multiple surveys have been done to gauge
HPV vaccine awareness and knowledge. These multi-
centre surveys in China showed that there was a high
acceptability of HPV vaccine to prevent CC among
Chinese women, but the price paid by individual should
be considered carefully when the vaccines become avail-
able [73, 74]. The vaccine safety and efficacy would be
the main concerns of HPV vaccine among Chinese [75].
Further proof of vaccine safety and efficacy and govern-
ment subsidies combined with increased awareness
could facilitate development and implementation of
HPV vaccination in China.
Our analyses assumed the cost of 3 doses of HPV
vaccine considering the registration clinical trial in China
is for 3-dose vaccine regime. While the WHO position
paper [13] on HPV vaccines proposed that the adoption of
a 2-dose vaccine schedule could be recommended for girls
aged 9–13 years. A 2-dose vaccine schedule might be
more cost-effectiveness due to the non-inferior efficacy
and less cost compared to 3-dose schedule.
Not only one-way sensitivity analysis, but also two-
way analysis and probabilistic analysis were performed
to certify the stability of the model. The main findings
in our study were consistent with the previous pub-
lished studies that evaluate the cost-effectiveness of
HPV vaccination in China [19, 20]. We all found that
combined HPV vaccination with screening would be
more cost-effectiveness than only screening under a
certain vaccine cost. The results in our study showed
Zhang et al. BMC Cancer  (2016) 16:848 Page 9 of 12
that adding vaccination to screening would reduce 60 %
more cancer, while the other study showed a 44 % can-
cer reduction [20]. And the discrepancies between our
study and others mainly occurred in the input parame-
ters. The parameters in our Markov model were col-
lected by multiple channels and validated by the expert
panel, in which the experts came from different regions
to fully capture the heterogeneity in disease burden,
health systems and socio-economic development of
China. The parameters were reliable and stable, which
were estimated based on the pooled Chinese databases
from multi-centre studies in rural and urban areas of 9
provinces across China [43]. Moreover, we used the most
recently updated data from National Bureau of Statistics
[23], China Cancer Registry [3] and Statistics of National
Health and Family Planning Commission [58].
Limitations also exist in the methods. Firstly, the
model did not capture the indirect protection resulting
from the herd immunity caused by the reduction of
circulation of the infective agent [76]. As a result, the
benefits of the vaccination could be underestimated.
Secondly, the vaccine efficacy in our model was assumed
to be life-long, however,but the vaccine efficacy clinical
trials have only lasted less than 10 years, so the duration
of vaccine efficacy is unknown. Thirdly, the end study
analysis of clinical registration trials of HPV vaccines in
China are ongoing [9, 10] and no final data for the vac-
cine efficacy against CIN2/3+ irrespective of HPV types
are available, so we adopted 93 % vaccine efficacy from
PATRICIA trial [49]. The assumption of lifelong dur-
ation of vaccination and the high efficacy could overesti-
mate the benefits of vaccination and result in more
favourable ICERs. Fourthly, one of the uncertainties
we have is whether HPV type replacement take place
once vaccination against HPV-16/18 is widespread. The
prevalence of HPV-16/18 falls to very low levels with
vaccination. Other oncogenic HPV subtypes currently
responsible for relatively few CC cases, might fill the
niche left by HPV-16/18. To date this question could
not be answered but available evidence suggests that
niche competition is unlikely to happen [77]. Lastly, the
present model only included cervical cancer and pre-
cancer, irrespective of the vulvar cancer, vaginal cancer,
anal and some proportion of oropharyngeal cancer
cancers that the HPV vaccine may have efficacy in
preventing [78–80]. If these diseases were included in
the evaluation, the protection offered by HPV vaccin-
ation would be wider, and would lead to a lower ICER
than the present analyses. These results are thus likely
to provide a conservative estimate.
Conclusions
In both rural and urban areas, the vaccination cost and
discounting are important factors determining the cost-
effectiveness of HPV vaccination; policy makers in China
should take these into account when making a decision
on the introduction of HPV vaccine. In areas with a high
burden of cervical cancer and limited screening activities,
HPV vaccination should be prioritized. However, the vac-
cine cost needs to be reduced in order to make it
very cost-effective and affordable as well, in particular in
poverty areas with high disease burden.
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